Nathaniel M. Lewis, PhD1,2,3; Rebecca B. Hershow, PhD1,2; Victoria T. Chu, MD1,2; Karen Wu, DVM1,2; Alison T. Milne, DEd4; Nathan LaCross, PhD3; Mary Hill, MPH5; Ilene Risk, MPA5; Adam L. Hersh, MD, PhD6; Hannah L. Kirking, MD1; Jacqueline E. Tate, PhD1; Snigdha Vallabhaneni, MD1; Angela C. Dunn, MD3 (View author affiliations)
During December 3, 2020–January 31, 2021, CDC, in collaboration with the University of Utah Health and Economic Recovery Outreach Project,* Utah Department of Health (UDOH), Salt Lake County Health Department, and one Salt Lake county school district, offered free, in-school, real-time reverse transcription–polymerase chain reaction (RT-PCR) saliva testing as part of a transmission investigation of SARS-CoV-2, the virus that causes COVID-19, in elementary school settings. School contacts† of persons with laboratory-confirmed SARS-CoV-2 infection, including close contacts, were eligible to participate (1). Investigators approached parents or guardians of student contacts by telephone, and during January, using school phone lines to offer in-school specimen collection; the testing procedures were explained in the preferred language of the parent or guardian. Consent for participants was obtained via an electronic form sent by e-mail. Analyses examined participation (i.e., completing in-school specimen collection for SARS-CoV-2 testing) in relation to factors§ that were programmatically important or could influence likelihood of SARS-CoV-2 testing, including race, ethnicity, and SARS-CoV-2 incidence in the community (2). Crude prevalence ratios (PRs) were calculated using univariate log-binomial regression.¶ This activity was reviewed by CDC and was conducted consistent with federal law and CDC policy.**
Among 856 unique student contacts at 20 elementary schools, 594 who were exposed to 33 index patients at 13 elementary schools were analyzed (Table).†† Among 594 student contacts, 438 (74%) participated (range = 59%–82% across schools), parents or guardians of 100 (17%) students refused, and 56 (9%) could not be reached (Table). Student testing outside of the investigation was not evaluated. Among 436 participants with available information,§§ parents or guardians of 230 (53%) consented to participation after the first contact attempt, an additional 134 (31%) after two attempts, and a further 72 (17%) after three attempts.
Compared with non-Hispanic White students, participation in the testing program was higher among students identifying as Hispanic/Latino White (PR = 1.21) and among members of a racial minority group¶¶ (PR = 1.19). Participation was higher in January (PR = 1.12) than in December. Compared with students living in ZIP codes with lower SARS-CoV-2 incidence than the median in all residential ZIP codes of students included in the analysis (11,461 cases per 100,000 persons), participation was higher among those living in ZIP codes with incidences higher than the median (PR = 1.12). No differences were found based on grade level, close contact with the index patient, having a family member ever receive a positive SARS-CoV-2 test result, cumulative school incidence, number of recent school cases, number of days from exposure to first contact or to testing, ZIP code–level deprivation score (a composite measure of socioeconomic disadvantage) (3), or ZIP code–level mask compliance, estimated as the percentage of adult residents who reported always wearing a mask in public.
In Utah’s socioeconomically disadvantaged areas, which have large proportions of uninsured and racial and ethnic minority residents, SARS-CoV-2 incidence is elevated, but testing rates are similar to those in other areas; this discrepancy could reflect a lack of access to testing (2). The sociodemographic differences in participation rates observed in this investigation could also suggest a higher level of concern about COVID-19 school safety among racial and ethnic minority parents (4) or less concern or better access to other testing resources among non-Hispanic White households. In-school specimen collection could therefore be a useful strategy for facilitating SARS-CoV-2 testing among those at higher risk for infection, who might also have limited access to testing. Higher participation in January compared with December could reflect the absence of potential holiday disincentives to testing or the investigation team’s use of school phone lines for recruitment in January.
As schools consider reopening, in-school specimen collection for SARS-CoV-2 testing could help reach potentially underserved populations to reduce community transmission (5,6). Explaining testing procedures in a parent’s or guardian’s preferred language, as was done in this situation, might also be important for promoting participation. One limitation is that testing was conducted among persons with a known SARS-CoV-2 exposure; in-school specimen collection without known exposures might result in different participation rates. A second limitation is that testing history among participants was not known; therefore, the degree to which access to testing in the community influenced participation is unknown. However, the high participation rate for RT-PCR saliva testing suggests potential scalability to other school testing strategies, including screening testing (7,8). School districts should continue universal mask use, physically distancing ≥3 ft (or as much as possible), and quarantining close contacts of persons with COVID-19 (8).
1CDC COVID-19 Response Team; 2Epidemic Intelligence Service, CDC; 3Utah Department of Health; 4Granite School District, Utah; 5Salt Lake County Health Department, Salt Lake City, Utah; 6Department of Pediatrics, Division of Infectious Diseases, University of Utah, Salt Lake City, Utah.
|Characteristic||No. (%)||Prevalence ratio (95% CI)|
|(N = 594)||(n = 438)|
|White, non-Hispanic||285||190 (66.7)||Ref|
|White, Hispanic/Latino||213||172 (80.8)||1.21 (1.09–1.35)|
|Racial minority†||96||76 (79.2)||1.19 (1.04–1.35)|
|Grade in school|
|Kindergarten–grade 2||258||197 (76.4)||Ref|
|Grades 3–4||162||118 (72.8)||0.95 (0.85–1.07)|
|Grades 5–6§||174||123 (70.7)||0.93 (0.82–1.04)|
|Identified as a close contact to index patient¶|
|Yes||166||124 (74.7)||1.02 (0.92–1.13)|
|Family member (including nonhousehold) ever received positive SARS-CoV-2 test result|
|Yes||60||49 (81.7)||1.12 (0.98–1.28)|
|Cumulative SARS-CoV-2 incidence rate by school|
|≤51 cases per 1,000 persons**||305||216 (70.8)||Ref|
|>51 cases per 1,000 persons||289||222 (76.8)||1.08 (0.99–1.19)|
|No. of school cases during 14 days before testing date|
|>4||192||138 (71.9)||0.96 (0.87–1.07)|
|Days from last school exposure to first time contacted††|
|5–7||331||245 (74.0)||0.99 (0.88–1.11)|
|8–12||118||85 (72.0)||0.97 (0.83–1.12)|
|Days from last school exposure to test date|
|8–10||278||207 (74.5)||1.02 (0.93–1.12)|
|Month of testing|
|January||367||282 (76.8)||1.12 (1.01–1.24)|
|ZIP code–level characteristic††|
|Cumulative SARS-CoV-2 incidence rate by ZIP code since March 2020|
|≤11,461 cases per 100,000 persons§§||301||210 (69.8)||Ref|
|>11,461 cases per 100,000 persons||292||228 (78.1)||1.12 (1.02–1.23)|
|Very low to average||315||226 (71.7)||Ref|
|High to very high||278||212 (76.3)||1.06 (0.97–1.17)|
|Masking compliance rate by ZIP code since May 2020|
|<81.6%||294||208 (70.7)||0.92 (0.84–1.01)|
MMWR and Morbidity and Mortality Weekly Report are service marks of the U.S. Department of Health and Human Services.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.
References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in MMWR were current as of the date of publication.
All HTML versions of MMWR articles are generated from final proofs through an automated process. This conversion might result in character translation or format errors in the HTML version. Users are referred to the electronic PDF version (https://www.cdc.gov/mmwr) and/or the original MMWR paper copy for printable versions of official text, figures, and tables.
Questions or messages regarding errors in formatting should be addressed to email@example.com.